Featuring over 65 Bioprocessing Facilities from China, Taiwan, Korea, Japan, India, Singapore and SEA
APAC’s Bioprocessing facilities 2020 covers bioprocessing facilities in China, Japan, Korea, Taiwan, SEA, and Australia. The 250 page report covers comprehensive information on parameters of manufacturing capabilities such as facility size, capacity, production technologies, type of biologics manufactured and much more. In addition, the directory features some of the checklists based on DesignFlex30 and highlights examples of companies that have constructed their facilities in a flexible manner catering to the fast-changing needs of the industry. It provides readers a closer look into the facilities of Chugai, Hanmi, Daiichi Sankyo, Biocon,( India & SEA) Beigene, Amgen (Singapore), GSK (Singapore), Biocon, AlphaMab, BeiGene, Innovent Biologics, Tot Biopharma and more!
KEY TAKEAWAYS!
- Understand the facilities expansion plans of key players in the industry
- Insights into the processes the various biopharma employ predominantly in each country and take a look into specific examples
- Potential clients who would be interested in your latest technology/ innovation /services that you offer
PURCHASE YOUR REPORT HERE!
For offline payments or inquiries, kindly contact Aisyah Atiqah at
e: aisyah.atiqah@imapac.com
t: +65 3109 0158
This license grants the right of use of the purchased report to a single recipient only. You may access the material on your computer, as and when required, for your own personal use.
Upto 3 users: This license grants the right of use of the purchased report by upto 3 users.
Unlimited user access (Within your organization): This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the number of users.
Section 1
• Preface
• Report Scope & Data Coverage
• IMAPAC’s Research Methodology
Section 2: Bioprocessing Facilities in Greater China
• Henlius Pharma
• Innovent Biologics
• Pfizer
• Tonhua Dongbao
• AlphaMab
• Akeso Pharmaceuticals
• Hanmi Pharma
• Sinovac
• BeiGene
• Junshi Biosciences
• Tot Biopharma
• Hualan Biological Engineering
Section 3: Bioprocessing Facilities In Korea And Japan
• Samsung Bioepis
• Astellas
• Celltrion
• Chugai
• Hanmi Pharma
• Kyowa Hakko Kirin
• Aprogen Biologiccs
• Daiichi Sankyo
Section 4: Bioprocessing Facilities In India And Australia
• Aurobindo
• CSL Bering
• Serum Institute of India
• CSIRO
• Enzene Biosciences
• Stelis Biopharma
Section 5: Bioprocessing Facilities In South-East-Asia
• Abbvie
• GSK
• AJ Biologics
• Amgen
• Novartis Thailand
• Baxter
• Takeda
• Siam Biosciences
Section 6: Region-Wise Data & Analysis Of Manufacturing Facility {Regions Covered: China, Taiwan, Japan& Korea, India, Australia & Sea}
• Products Manufactured: Vaccines| Cell Therapy| Recombinant Proteins & Mabs | Others
• Technologies Housed and Bioprocessing Processes
• Plant Capacity
• Projects In Pipeline
• Biomanufacturing Investment
• Regulatory Approvals
• Facility Size, Design
• Financial Insights
• Pestel Analysis
Section 7: Our Other Reports
• Bibiliography
• Disclaimer
• About Us
• Our Other Reports
English 
简体中文 
日本語 
한국어 
繁體中文